global messaging alerts

Meet the BD Team

Meet the ApiJect Business Development Team

Our Approach

At ApiJect, our Business Development team partners with you to provide a turnkey combination product development through commercial manufacturing solution using our single-use blow-fill-seal injection platform.  We work with you to identify the appropriate injector device design, ensure ensure feasibility and identify a manufacturing solution that best fits your injectable or vaccine needs.

Bo Kowalczyk, Senior Vice President, Business Development

Prior to joining ApiJect, Bo served as the Vice President of Sales, North America, for Syngene International’s Chemical Development and Manufacturing division, where he aligned operational expertise with prospecting efforts to target the right opportunities and maximize client satisfaction.

Bo served as Global VP, Business Development and Marketing with Eurofins Biologics Bioanalytical Services where he led efforts to integrate Bioanalytical Services with Eurofins Central Lab Services to provide seamless services for clinical trial logistics and sample testing support. He served as Vice President, Business Development and Marketing at AIT Bioscience where he successfully grew sales & profitability over a 5- year period in part by creating a network of third-party preclinical toxicology service providers allowing AIT Bioscience earlier access to promising therapeutic candidates moving into clinical trials.

Kevin Ostrander, Vice President, Business Development

Kevin brings nearly 30 years of pharmaceutical experience executing a multitude of business development strategies, including in/out licensing, acquisition of products, corporate divestments, joint ventures and strategic partnerships, as well as, creating and running platform collaborations. He has completed more than 75 transactions with a valuation exceeding $1B.

Prior to joining ApiJect, Kevin was Sr. VP of Business Development at BioDelivery Sciences International and was instrumental in the sale of the business to Collegium Pharmaceuticals for an equity value of $604MM. He has held BD roles with Glenmark Pharmaceuticals, Sandoz, Mylan, Eurand (Aptalis), Watson Pharmaceuticals and Elan Drug Delivery. He started his career as a product development scientist with Sterling Drug, Nycomed and NanoSystems. Kevin holds 13 US patents in the areas of nanotechnology and medical devices. He has authored several publications in peer review journals and is an invited speaker at many industry conferences and the FDA.


Cindy Benedict, Executive Director, Business Development

Cindy has been active in pharmaceutical business development and licensing for more than a decade.  During her tenure, she has closed licensing, development, merger, and acquisition and authorized generic deals; and led various cross-functional due diligence activities.

Prior to joining ApiJect, Cindy was the Director, Business Development & Licensing, at Midas Pharmaceuticals, where she identified and negotiated business development opportunities and transactions for the North American market. She has secured Business Development positions at Amneal Pharmaceuticals, Sandoz and CorePharma (Impax/Amneal) with a strong focus on generic pharmaceuticals and 505b2 opportunities.  Additionally, she held Clinical Supply Chain and Manufacturing positions at ImClone Systems (Lilly).

Additional Technical Resources

random footer image
Social media & sharing icons powered by UltimatelySocial